Overview

Efficacy and Safety of Doravirine in the Rapid Initiation

Status:
NOT_YET_RECRUITING
Trial end date:
2028-01-13
Target enrollment:
Participant gender:
Summary
Protocol title: "Efficacy and safety of doravirine in the rapid initiation of highly active antiretroviral therapy (HAART) in HIV-1positive patients without prior treatment."
Phase:
PHASE4
Details
Lead Sponsor:
Fundacin Husped
Collaborators:
Fundacion IDEAA
MSD Pharmaceuticals LLC
Treatments:
doravirine
Lamivudine
Tenofovir